CGEN Company Profile and Key Details
Compugen Ltd.
CGEN Stock Price Chart
Stock Price Today
Compugen Ltd. (CGEN) stock declined over -2.15%, trading at $2.28 on NASDAQ, down from the previous close of $2.33. The stock opened at $2.21, fluctuating between $2.18 and $2.32 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Company Information
| Employees | 68 |
| Beta | 2.65 |
| Sales or Revenue | $33.46M |
| 5Y Sales Change% | 0.186% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Compugen Ltd. (NASDAQ: CGEN) stock price is $2.28 in the last trading session. During the trading session, CGEN stock reached the peak price of $2.32 while $2.18 was the lowest point it dropped to. The percentage change in CGEN stock occurred in the recent session was -2.15% while the dollar amount for the price change in CGEN stock was -$0.05.
The NASDAQ listed CGEN is part of Biotechnology industry that operates in the broader Healthcare sector. Compugen Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Zurit Levine
Senior Vice President of Technology Innovation
Mr. Alberto Sessa
Chief Financial Officer
Ms. Dorit Amitay
Vice President of HR
Dr. Yaron Turpaz M.B.A., Ph.D., MBA
Senior Vice President & Sr. Advisor of Computational Discovery
Rivka Schwartz
Vice President Research and Discovery
Mr. Eran Ben Dor
Gen. Counsel & Corporation Sec.
Ms. Yvonne Naughton
Head of Investor Relations & Corporation Communications
Dr. Henry Adewoye M.D.
Senior Vice President & Chief Medical Officer
Dr. Anat Cohen-Dayag Ph.D.
Chief Executive Officer, Pres & Director
Dr. Oliver Froescheis Ph.D.
Senior Vice President of Corporation & Bus. Devel.
Dr. Zurit Levine Ph.D.
Senior Vice President of Technology Innovation
Dr. Yaron Turpaz M.B.A., MBA, Ph.D.
Senior Vice President & Sr. Advisor of Data and Informatics Solutions
Dr. Eran Ophir Ph.D.
Chief Scientific Officer
CGEN's closing price is 72.59% higher than its 52-week low of $1.35 where as its distance from 52-week high of $3.03 is -23.1%.
Number of CGEN employees currently stands at 68.
Official Website of CGEN is: https://cgen.com
CGEN could be contacted at phone 972 376 58585 and can also be accessed through its website. CGEN operates from Azrieli Center, Holon, 5885849, Israel.
CGEN stock volume for the day was 546.67K shares. The average number of CGEN shares traded daily for last 3 months was 640.83K.
The market value of CGEN currently stands at $204.14M with its latest stock price at $2.28 and 89.54M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com